Gene therapy for lung disease: Hype or hope?

Annals of Internal Medicine

Volumn 132, Issue 8, 2000, Pages 649-660

  Albelda, Steven M ^a,b   Wiewrodt, Rainer ^a,b   Zuckerman, Jonathan B ^a,c  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b Maine Medical Center ^*  (United States)

^c MAINE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ALPHA 1 ANTITRYPSIN DEFICIENCY; CANCER IMMUNOTHERAPY; CYSTIC FIBROSIS; GENE TARGETING; GENE THERAPY; HUMAN; LUNG CANCER; PRIORITY JOURNAL; REVIEW; SUICIDE GENE; THORAX CANCER; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

EID: 0034681968     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-132-8-200004180-00008     Document Type: Review

References (116)

1. Anderson WF. Human gene therapy. Science. 1992;256:808-13.
2. Anderson WF. Human gene marker/therapy clinical protocols. Hum Gene Ther. 1999;10:2037-88.
3. Ramsey BW. Drug therapy: management of pulmonary disease in patients with cystic fibrosis. N Engl J Med. 1996;335:179-88.
4. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med. 1996;154:1229-55.
5. Curiel DT, Pilewsky JM, Albelda SM. Gene therapy approaches for inherited and acquired lung diseases. Am J Respir Cell Mol Biol. 1996;14:1-18.
6. Verma IM, Somia N. Gene therapy - promises, problems and prospects. Nature. 1997;389:239-42
7. Wivel NA, Wilson JM. Methods of gene delivery. Hematol Oncol Clin North Am. 1998;12:483-501.
8. Zhang WW. Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther. 1999;6:113-38.
9. Yeh P, Perricaudet M. Advances in adenoviral vectors: from genetic engineering to their biology. FASEB J. 1997;11:615-23.
10. Worgall S, Wolff G, Falck-Pedersen E, Crystal RG. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther. 1997;8:37-44.
11. Wold WS, Doronin K, Toth K, Kuppuswamy M, Lichtenstein DL, Tollefson AE. Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic. Curr Opin Immunol. 1999;11:380-6.
12. Yang Y, Nunes FA, Berencsi K, Furth EE, Gönczöl E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A. 1994;91:4407-11.
13. Gahéry-Ségard H, Farace F, Godfrin D, Gaston J, Lengagne R, Tursz T, et al. Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J Virol. 1998;72:2388-97.
14. Harvey BG, Hackett NR, El-Sawy T, Rosengart TK, Hirschowitz EA, Lieberman MD, et al. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J Virol. 1999;73:6729-42.
15. Molnar-Kimber KL, Sterman DH, Chang M, Kang EH, ELBash M, Lanuti M, et al. Impact of preexistng and induced humoral and cellular immune responses in an adenoviral-based gene Therapy phase I clinical trial for localized malignancy. Hum Gene Ther. 1998;9:2121-33.
16. Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell. 1996;85:229-36.
17. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zazloff M, Wilson JM. Human β-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell. 1997;88:553-60.
18. Johnson LG, Olsen JC, Sarkadi B, Moore KL, Swanstrom R, Boucher RC. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet. 1992;2:21-5.
19. Johnson LG, Boyles SE, Wilson J, Boucher RC. Normalization of raised sodium absorption and raised calcium-mediated chloride secretion by adenovirus-mediated expression of cystic fibrosis transmembrane conductance regulator in primary human cystic fibrosis airway epithelial cells. J Clin Invest. 1995;95:1377-82.
20. Zabner J, Couture LA, Gregory RJ, Graham SM, Smith AE, Welsh MJ. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients witn cystic fibrosis. Cell. 1993;75: 207-16.
21. Crystal RG, McElvaney NG, Rosenfeld MA, Chu CS, Mastrangeli A, Hay JG, et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet. 1994;8:42-51.
22. Hay JG, McElvaney NG, Herena J, Crystal RG. Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector. Hum Gene Ther. 1995;6:1487-96.
23. Knowles MR, Hohneker KW, Zhou Z, Olsen JC, Noah TL, Hu PC, et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med. 1995;333:823-31.
24. Zabner J, Ramsey BW, Meeker DP, Aitken ML, Balfour RP, Gibson RL, et al. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J Clin Invest. 1996;97:1504-11.
25. Bellon G, Michel-Calemard L, Thouvenot D, Jagneaux V, Poitevin F, Malcus C, et al. Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Hum Gene Ther. 1997;8:15-25.
26. Zuckerman JB, Robinson CB, McCoy KS, Shell R, Sferra TJ, Chirmule N, et al. A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. Hum Gene Ther. 1999;10:2973-85.
27. Wagner JA, Moran ML, Messner AH, Daifuku R, Conrad CK, Reynolds T, et al. A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis. Hum Gene Ther. 1998;9:889-909.
28. Wagner JA, Reynolds T, Moran ML, Moss RB, Wine JJ, Flotte TR, et al. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet. 1998;351:1702-3.
29. Caplen NJ, Alton EW, Middleton PG, Dorin JR, Stevenson BJ, Gao X, et al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med. 1995;1:39-46.
30. Gill DR, Southern KW, Mofford KA, Seddon T, Huang L, Sorgi F, et al. A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther. 1997;4:199-209.
31. Porteous DJ, Dorin JR, McLachlan G, Davidson-Smith H, Davidson H, Stevenson BJ, et al. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther. 1997;4:210-8.
32. Flotte TR, Carter BJ. In vivo gene therapy with adeno-associated virus vectors for cystic fibrosis. Adv Pharmacol. 1997;40:85-101.
33. Ferrari FK. Xiao X, McCarty D, Samulski RJ. New developments in the generation of Ad-free, high-titer rAAV gene therapy vectors. Nat Med. 1997;3:1295-7.
34. Rubenstein RC, McVeigh U, Flotte TR, Guggino WB, Zeitlin PL. CFTR gene transduction in neonatal rabbits using an adeno-associated virus (AAV) vector. Gene Ther. 1997;4:384-92.
35. Conrad CK, Allen SS, Afione SA, Reynolds TC, Beck SE, Fee-Maki M, et al. Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Ther. 1996;3:658-68.
36. Flotte T, Carter B, Conrad C, Guggino W, Reynolds T, Rosenstein B, et al. A phase I study of adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gene Ther. 1996;7:1145-59.
37. Halbert CL, Alexander IE, Wolgamot GM, Miller AD. Adeno-associated virus vectors transduce primary cells much less efficiently than immortalized cells. J Virol. 1995;69:1473-9.
38. Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand synthesis is a rate-lim ting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol. 1996;70:3227-34.
39. Teramato S, Bartlett JS, McCarty D, Xiao X, Samulski RJ, Boucher RC. Factors influencing adeno-associated virus-mediated gene transfer to human cystic fibrosis airway epithelial cells: comparison with adenovirus vectors. J Virol. 1998;72:8904-12.
40. Kearns WG, Afione SA, Fulmer SB, Pang MC, Erikson D, Egan M, et al. Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line. Gene Ther. 1996;3:748-55.
41. Scheule RK, St George JA, Bagley RG, Marshall J, Kaplan JM, Akita GY, et al. Basis of pulmonary toxidty associated with cationic lipid-mediated gene transfer to the mammalian lung. Hum Gene Ther. 1997;8:686-707.
42. Yew NS, Wang KX, Przybylska M, Bagley RG, Stedman M, Marshall J, et al. Contribution of plasmid DNA to inflammation in the lung after administration of cationic lipid:pDNA complexes. Hum Gene Ther. 1999;10: 223-34.
43. Mansoura MK, Biwersi J, Ashlock MA, Verkman AS. Fluorescent chloride indicators to assess the efficacy of CFTR cDNA delivery. Hum Gene Ther. 1999;10:861-75.
44. Knowles MR, Noone PG, Hohneker K, Johnson LG, Boucher RC, Efthimiou J, et al. A double-blind, placebo controlled, dose ranging study to evaluate the safety and biological efficacy of the lipid-DNA complex GR213487B in the nasal epithelium of adult patients with cystic fibrosis. Hum Gene Ther. 1998;9:249-69.
45. Sorscher EJ, Logan JJ, Frizzell RA, Lyrene RK, Bebok Z, Dong JY, et al. Gene therapy for cystic fibrosis using cationic liposome mediated gene transfer: a phase I trial of safety and efficacy in the nasal airway. Hum Gene Ther. 1994;5:1259-77.
46. Stoller JK. Clinical features and natural history of severe alpha 1-antitrypsin deficiency. Roger S. Mitchell Lecture. Chest. 1997;111:1235-1285.
47. Crystal RG, Brantly ML, Hubbard RC, Curiel DT, States DJ, Holmes MD. The alpha 1-antitrypsin gene and its mutations. Clinical consequences and strategies for therapy. Chest. 1989;95:196-208.
48. Knoell DL, Wewers MD. Clinical implications of gene therapy for alpha 1-antitrypsin deficiency. Chest. 1995;107:535-45.
49. Garver RI Jr, Chytil A, Courtney M, Crystal RG. Clonal gene therapy: transplanted mouse fibroblast clones express the alpha 1-antitrypsin gene in vivo. Science. 1987;237:762-4.
50. Jaffe HA, Danel C, Longenecker G, Metzger M, Setoguchi Y, Rosenfeld MA, et al. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat Genet. 1992;1:372-8.
51. Kay MA, Li Q, Liu TJ, Leland F, Toman C, Finegold M, et al. Hepatic gene therapy persistent expression of human alpha 1-antitrypsin in mice after direct gene delivery in vivo. Hum Gene Ther. 1992;3:641-7.
52. Rosenfeld MA, Siegfried W, Yoshimura K, Yoneyama K, Fukayama M, Stier LE, et al. Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. Science. 1991;252:431-4.
53. Canonico AE, Conary JT, Meyrick BO, Brigham KL. Aerosol and intravenous transfection of human alpha 1-antitrypsin gene to lungs of rabbits. Am J Respir Cell Mol Biol. 1994;10 24-9.
54. Schiedner G, Morral N, Parks RJ, Wu Y, Koopmans SC, Langston C, et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet. 1998; 18:180-3.
55. Song S, Morgan M, Ellis T, Poirier A, Chesnut K, Wang J, et al. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci U S A. 1998; 95:14384-8.
56. Xiao W, Berta SC, Lu MM, Moscioni AD, Tazelaar J, Wilson JM. Adeno-associated virus as a vector for liver-directed gene therapy. J Virol. 1998;72:10222-6.
57. Muzykantov VR. Immunotargeting of drugs to the pulmonary vascular endothelium as a therapeutic strategy. Pathophysiology. 1998;S:15-33.
58. Rodman DM, San H, Simari R, Stephan D, Tanner F, Yang Z, et al. In vivo gene delivery to the pulmonary circulation in rats: transgene distribution and vascular inflammatory response. Am J Respir Cell Mol Biol. 1997;16: 640-9.
59. Dow SW, Fradkin LG, Liggitt DH, Willson AP, Heath TD, Potter TA. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol. 1999; 163:1552-61.
60. Conary JT, Parker RE, Christman BW, Faulks RD, King GA, Meyrick BO, et al. Protection of rabbit lungs from endotoxin injury by in vivo hyperexpression of the prostaglandin G/H synthase gene. J Clin Invest. 1994; 93:1834-40.
61. Fouty B, Rodman DM. Pulmonary vascular gene transfer: prospects for successful therapy of pulmonary hypertension. Am J Respir Cell Mol Biol. 1999;21:555-7.
62. Boasquevisque CH, Mora BN, Boglione M, Ritter JK, Scheule RK, Yew N, et al. Liposome-mediated gene transfer in rat lung transplantation: a comparison between the in vivo and ex vivo approaches. J Thorac Cardiovasc Surg. 1999;117:8-14.
63. Engelhardt JF. Redox-mediated gene therapies for environmental injury: approaches and concepts. Antioxidants & Redox Signaling. 1999;1:5-27.
64. Erzurum SC, Lemarchand P, Rosenfeld MA, Yoo JH, Crystal RG. Protection of human endothelial cells from oxidant injury by adenovirus-mediated transfer of the human catalase cDNA. Nucleic Acids Res. 1993;21: 1607-12.
65. Danel C, Erzurum SC, Prayssac P, Eissa NT, Crystal RG, Herve P, et al. Gene therapy for oxidant injury-related diseases: adenovirus-mediated transfer of superoxide dismutase and catalase cDNAs protects against hyperoxia but not against ischemia-reperfusion lung injury. Hum Gene Ther. 1998;9: 1487-96.
66. Epperly M, Bray J, Kraeger S, Zwacka R, Engelhardt J, Travis E, et al. Prevention of late effects of irradiation lung damage by manganese superoxide dismutase gene therapy. Gene Ther. 1998;5:196-208.
67. Eastman SJ, Lukason MJ, Tousignant JD, Murray H, Lane MD, St George JA, et al. A concentrated and stable aerosol formulation of cationic lipid:DNA complexes giving high-level gene expression in mouse lung. Hum Gene Ther. 1997;8:765-73.
68. Yei S, Bachurski CJ, Weaver TE, Wert SE, Trapnell BC, Whitsett JA. 1994. Adenoviral-mediated gene transfer of human surfactant protein B to respiratory epithelial cells. Am J Respir Cell Mol Biol. 1994;11:329-36.
69. Korst RJ, Bewig B, Crystal RG. In vitro and in vivo transfer and expression of human surfactant SP-A-and SP-B-associated protein cDNAs mediated by replication-deficient, recombinant adenoviral vectors. Hum Gene Ther. 1995; 6:277-87.
70. Mathieu M, Gougat C, Jaffuel D, Danielsen M, Godard P, Bousquet J, et al. The glucocorticoid receptor gene as a candidate for gene therapy in asthma. Gene Ther. 1999;6:245-52.
71. Hogan SP, Foster PS, Tan X, Ramsay AJ. Mucosal IL-12 gene delivery inhibits allergic airways disease and restores local antiviral immunity. Eur J Immunol. 1998;28:413-23.
72. Dow SW, Schwarze J, Heath TD, Potter TA, Gelfand EW. Systemic and local interferon gamma gene delivery to the lungs for treatment of allergen-induced airway hyperresponsiveness in mice. Hum Gene Ther. 1999;10: 1905-14.
73. Carbone DP, Minna JD. The molecular genetics of lung cancer. Adv Intern Med. 1992;37:153-71.
74. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med. 1996;2:985-91.
75. Tursz T, Cesne AL, Baldeyrou P, Gautier E, Opolon P, Schatz C, et al. Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients. J Natl Cancer Inst. 1996;88:1857-63.
76. Gahéry-Sègard H, Molinier-Frenkel V, Le Boulaire C, Saulnier P, Opolon P, Lengagne R, et al. Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J Clin Invest. 1997;100:2218-26.
77. Schuler M, Rochlitz C, Horowitz JA, Schlegel J, Perruchoud AP, Kommoss F, et al. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum Gene Ther. 1998;9:2075-82.
78. Swisher SG, Roth JA, Neumanaitis J, Lawrence DD, Kemp BL, Carrasco CH, et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:763-71.
79. Sterman DH, Treat J, Litzky LA, Amin KM, Coonrod L, Molnar-Kimber KL, et al. Adenovirus-mediated herpes simplex virus thymidme kinase/ganciclovir gene therapy in patients with localized malignancy results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther. 1998;9:1083-92.
80. Mukherjee S, Haenel T, Epton M, Lake R, Harnett G, Phillips P, et al. Intralesional vaccinia virus-interleukin-2 (VV-IL-2) gene therapy n malignant mesothelioma (MM) [Abstract]. Lung Cancer. 1997;18(1 Suppl):236.
81. Robinson BW, Mukherjee SA, Davidson A, Morey S, Musk AW, Ramshaw I, et al. Cytokine gene therapy or infusion as treatment for solid human cancer. J Immunother. 1998;21:211-7.
82. Schwarzenberger P, Harrison L, Weinacker A, Gaumer R, Theodossiou C, Summer W, et al. Gene therapy for malignant mesothelioma: a novel approach for an incurable cancer with increased incidence in Louisiana. J La State Med Soc. 1998;150:168-74.
83. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 1994;54:2287-91.
84. Roth JA. Gene replacement strategies for lung cancer. Curr Opin Oncol. 1998;10:127-32.
85. Rizk NP, Chang MV, El Kouri C, Seth P, Kaiser LR, Albelda SM, et al. The evaluation of adenoviral p53-mediated bystander effect in gene therapy for cancer. Cancer Gene Ther. 1999;6:291-301.
86. Van Meir EG, Polverini PJ, Chazin VR, Su Huang HJ, de Tribolet N, Cavenee WK. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat Genet. 1994;8:171-6.
87. Fukazawa T, Fujiwara T, Morimoto Y, Shao J, Nishizaki M, Kadowaki Y, et al. Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells. Oncogene. 1999;18:2189-99.
88. Moolten FL. Drug sensitivity ("suicide") genes for selective cancer therapy. Cancer Gene Ther. 1994;1:279-87.
89. Pope IM, Poston GJ, Kinsella AR. The role of the bystander effect in suicide gene therapy. Eur J Cancer. 1997;33:1005-16.
90. Elshami AA, Saavedra A, Zhang H, Kucharczuk JC, Spray DC, Fishman GI, et al. Gap junctions play a rote in the "bystander effect" of the Herpes Simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther. 1996; 3:85-92.
91. Freeman SM, Ramesh R, Marrogi AJ. Immune system in suicide-gene therapy Lancet. 1997;349:2-3.
92. Dubinett SM, Miller PW, Sharma S, Batra RK. Gene therapy for lung cancer. Hematol Oncol Clin North Am. 1998;12:569-94.
93. Lee CT, Wu S, Ciernik IF, Chen H, Nadaf-Rahrov S, Gabrilovich D, et al. Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor. Hum Gene Ther. 1997; 8:187-93.
94. Simons JW, Jaffee EM, Weber CE, Levitsky HI, Nelson WG, Carducci MA, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 1997;57:1537-46.
95. Chen SH, Chen XH, Wang Y, Kosai K, Finegold MJ, Rich SS, et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci U S A. 1995;92:2577-81.
96. Kolls J, Freeman S, Ramesh R, Marroqi A, Weinacker A, Summer W, et al. The treatment of malignant pleura mesothelioma with gene modified cancer cells: a phase I study [Abstract]. Am J Respir Crit Care Med. 1998; 157:A563.
97. Boucher RC. Status of gene therapy for cystic fibrosis lung disease. J Clin Invest. 1999;103:441-5.
98. Wang G, Slepushkin V, Zabner J, Keshavjee S, Johnston JC, Sauter SL, et al. Feline immunodeficiency virus vectors persistently transauce non-dividing airway epithelia and correct the cystic fibrosis defect. J Clin Invest. 1999;104:R55-R62.
99. Russell SJ. Replicating vectors for gene therapy of cancer: risks, limitations and prospects. Eur J Cancer. 1994;30A:1165-71.
100. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med. 1997;3:639-45.
101. Roderiguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 1997;57:2559-63.
102. Lorence RM, Katubig BB, Reichard KW, Reyes HM, Phuangsab A, Sassetti MD, et al. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res. 1994;54:6017-21.
103. Kucharczuk JC, Randazzo B, Chang MY, Amin KM, Elshami AA, Sterman DH, et al. Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma. Cancer Res. 1997;57:466-71.
104. Bilbao G, Contreras JL, Gómez-Navarro J, Curiel DT. Improving adenoviral vectors for cancer gene therapy. Tumor Targeting. 1998;3:59-79.
105. Vilquin JT, Guérette B, Kinoshita I, Roy B, Goulet M, Gravel C, et al. FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. Hum Gene Ther. 1995; 6:1391-401.
106. Smith TA, White BD, Gardner JM, Kaleko M, McClelland A. Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Ther. 1996;3:496-502.
107. Jooss K, Yang Y, Wilson JM. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum Gene Ther. 1996;7:1555-66.
108. Chillón M, Lee JH, Fasbender A, Welsh MJ. Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro. Gene Ther. 1998;5:995-1002.
109. O'Riordan CR, Lachapelle A, Delgado C, Parkes V, Wadsworth SC, Smith AE, et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther. 1999;10:1349-58.
110. Ohira T, One Y, Heike Y, Podack ER, Olsen KJ, Nishio K, et al. Gene therapy for Lewis lung carcinoma with tumor necrosis factor and interleukin 2 cDNAs co-transfected subline. Gene Ther. 1994;1:269-75.
111. Esandi MC, van Someren GD, Bout A, Mulder AH, van Bekkum DW, Valerio D, et al. IL-1/IL-3 gene therapy of non-small cell lung cancer (NSCLC) in rats using 'cracked' adenoproducer cells. Gene Ther. 1998;5: 778-88.
112. Sharma S, Wang J, Huang M, Paul RW, Lee P, McBride WH, et al. Interleukin-7 gene transfer in non-small-cell lung cancer decreases tumor proliferation, modifies cell surface molecule expression, and enhances antitumor reactivity. Cancer Gene Ther. 1996;3:302-13.
113. Miller PW, Sharma S, Stolina M. Butterfield LH, Luo J, Lin Y, et al. Ilntratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. Hum Gene Ther. 2000;11:53-65.
114. Huang M, Stolina M, Sharma S, Mao JT, Zhu L, Miller PW, et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res. 1998;58: 1208-16.
115. Kong HL, Crystal RG. Gene therapy strategies for tumor angiogenesis. J Natl Cancer Inst. 1998;90:273-86.
116. Frederiksen K, Petri A, Abrahamsen N, Poulsen H. Gene therapy for lung cancer. Lung Cancer. 1999;23:191-207.